Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 2245 total matches.

Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
of chronic hepatitis C virus (HCV) genotype 1 or 4 infection. Pronunciation Key Elbasvir : elb' as veer ...
The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):25-7 | Show Introduction Hide Introduction

Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012  (Issue 1402)
-antihistamine, such as loratadine (Claritin, and generics) or fexofenadine (Allegra, and generics).1 ...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Med Lett Drugs Ther. 2012 Oct 29;54(1402):85-7 | Show Introduction Hide Introduction

Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1 ...
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations. About 25% of patients with advanced NSCLC have tumors with high levels of PD-L1 expression (PD-L1 expressed on ≥50% of tumor cells). Pembrolizumab was approved earlier for treatment...
Med Lett Drugs Ther. 2017 Jan 30;59(1513):22-3 | Show Introduction Hide Introduction

Semaglutide (Wegovy) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
of obesityrelated comorbidities.4 MECHANISM OF ACTION — Activation of brain GLP-1 receptors potentiates glucose ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has now been approved in a higher dose as Wegovy (Novo Nordisk) for chronic weight management in adults with or without type 2 diabetes who have a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia). An oral formulation of semaglutide...
Med Lett Drugs Ther. 2021 Jul 12;63(1628):106-8 | Show Introduction Hide Introduction

Alpha1-Proteinase Inhibitor for Alpha1-Antitrypsin Deficiency

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 1988  (Issue 761)
FOR ONLINE USERS ALPHA 1 -PROTEINASE INHIBITOR FOR ALPHA 1 -ANTITRYPSIN DEFICIENCY Human alpha 1 ...
Human alpha1-proteinase inhibitor (Prolastin Cutter), possibly better known as alpha1-antitypsin (ATT), is now available in the USA for replacement therapy in patients with emphysema who have a congential deficiency of the protein.
Med Lett Drugs Ther. 1988 Mar 11;30(761):29-30 | Show Introduction Hide Introduction

Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019  (Issue 1564)
in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water ...
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water for dissolution and ingestion of 1 L of clear fluid in addition.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):11-4 | Show Introduction Hide Introduction

Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
trials included applicationsite pain (10.6%), dryness (4.9%), exfoliation (4.1%), erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream containing the retinoid tretinoin and the oxidizing agent benzoyl peroxide, for once-daily topical treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2022 May 16;64(1650):75-6 | Show Introduction Hide Introduction

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
a cephalosporin or a carbapenem with a beta-lactamase inhibitor such as ceftazidime/ avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 | Show Introduction Hide Introduction

Antibacterial Prophylaxis for Dental, GI and GU Procedures

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005  (Issue 1213)
practice has never been established by controlled trials in humans. 1 The drugs and dosages in the table ...
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Med Lett Drugs Ther. 2005 Jul 18;47(1213):59-60 | Show Introduction Hide Introduction

Trifarotene (Aklief) - A New Topical Retinoid for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019  (Issue 1587)
by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream (Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for treatment of acne; tretinoin (Retin-A, and others), adapalene (Differin, and generics), and tazarotene (Tazorac, and others) have been available by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment of acne in patients ≥12 years old.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):195-7 | Show Introduction Hide Introduction